First clinical application of an actively reversible direct factor ixa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention

Mauricio G Cohen, Drew A. Purdy, Joseph S. Rossi, Liliana R. Grinfeld, Shelley K. Myles, Laura H. Aberle, Adam B. Greenbaum, Edward Fry, Mark Y. Chan, Ross M. Tonkens, Steven Zelenkofske, John H. Alexander, Robert A. Harrington, Christopher P. Rusconi, Richard C. Becker

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Background: The ideal anticoagulant should prevent ischemic complications without increasing the risk of bleeding. Controlled anticoagulation is possible with the REG1 system, an RNA aptamer pair comprising the direct factor IXa inhibitor RB006 and its active control agent RB007. Methods and Results: This phase 2a study included a roll-in group (n=2) treated with REG1 plus glycoprotein IIb/IIIa inhibitors followed by 2 groups randomized 5:1 to REG1 or unfractionated heparin. In group 1 (n=12), RB006 was partially reversed with RB007 after percutaneous coronary intervention and fully reversed 4 hours later. In group 2 (n=12), RB006 was fully reversed with RB007 immediately after percutaneous coronary intervention. Femoral sheaths were removed after complete reversal. Patients were pretreated with aspirin and clopidogrel. End points included major bleeding within 48 hours; composite of death, myocardial infarction, or urgent target vessel revascularization within 14 days; and pharmacodynamic measures. All cases were successful, with final Thrombolysis in Myocardial Infarction grade 3 flow and no angiographic thrombotic complications. There were 2 ischemic end points in the REG1 group and 1 in the unfractionated heparin group, with 1 major bleed in the unfractionated heparin group. Median activated clotting time values rose from 151 to 236 seconds after RB006. Administration of the partial RB007 dose reversed anticoagulation to an intermediate activated clotting time value of 186 seconds. Complete reversal with RB007 returned the median activated clotting time value to 144 seconds. Both reversal strategies enabled scheduled femoral sheath removal. Conclusions: This study demonstrates the clinical translation of a novel platform of anticoagulation targeting factor IXa and its active reversal to percutaneous coronary intervention and provides the basis for further investigation.

Original languageEnglish
Pages (from-to)614-622
Number of pages9
JournalCirculation
Volume122
Issue number6
DOIs
StatePublished - Aug 10 2010

Fingerprint

Percutaneous Coronary Intervention
Factor IXa
Heparin
clopidogrel
Thigh
Myocardial Infarction
Nucleotide Aptamers
Hemorrhage
Platelet Glycoprotein GPIIb-IIIa Complex
Anticoagulants
Aspirin

Keywords

  • angioplasty
  • anticoagulants
  • coronary disease
  • thrombosis

ASJC Scopus subject areas

  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

First clinical application of an actively reversible direct factor ixa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. / Cohen, Mauricio G; Purdy, Drew A.; Rossi, Joseph S.; Grinfeld, Liliana R.; Myles, Shelley K.; Aberle, Laura H.; Greenbaum, Adam B.; Fry, Edward; Chan, Mark Y.; Tonkens, Ross M.; Zelenkofske, Steven; Alexander, John H.; Harrington, Robert A.; Rusconi, Christopher P.; Becker, Richard C.

In: Circulation, Vol. 122, No. 6, 10.08.2010, p. 614-622.

Research output: Contribution to journalArticle

Cohen, MG, Purdy, DA, Rossi, JS, Grinfeld, LR, Myles, SK, Aberle, LH, Greenbaum, AB, Fry, E, Chan, MY, Tonkens, RM, Zelenkofske, S, Alexander, JH, Harrington, RA, Rusconi, CP & Becker, RC 2010, 'First clinical application of an actively reversible direct factor ixa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention', Circulation, vol. 122, no. 6, pp. 614-622. https://doi.org/10.1161/CIRCULATIONAHA.109.927756
Cohen, Mauricio G ; Purdy, Drew A. ; Rossi, Joseph S. ; Grinfeld, Liliana R. ; Myles, Shelley K. ; Aberle, Laura H. ; Greenbaum, Adam B. ; Fry, Edward ; Chan, Mark Y. ; Tonkens, Ross M. ; Zelenkofske, Steven ; Alexander, John H. ; Harrington, Robert A. ; Rusconi, Christopher P. ; Becker, Richard C. / First clinical application of an actively reversible direct factor ixa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. In: Circulation. 2010 ; Vol. 122, No. 6. pp. 614-622.
@article{d2ae0e2d9c714534896a73e29b66fd94,
title = "First clinical application of an actively reversible direct factor ixa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention",
abstract = "Background: The ideal anticoagulant should prevent ischemic complications without increasing the risk of bleeding. Controlled anticoagulation is possible with the REG1 system, an RNA aptamer pair comprising the direct factor IXa inhibitor RB006 and its active control agent RB007. Methods and Results: This phase 2a study included a roll-in group (n=2) treated with REG1 plus glycoprotein IIb/IIIa inhibitors followed by 2 groups randomized 5:1 to REG1 or unfractionated heparin. In group 1 (n=12), RB006 was partially reversed with RB007 after percutaneous coronary intervention and fully reversed 4 hours later. In group 2 (n=12), RB006 was fully reversed with RB007 immediately after percutaneous coronary intervention. Femoral sheaths were removed after complete reversal. Patients were pretreated with aspirin and clopidogrel. End points included major bleeding within 48 hours; composite of death, myocardial infarction, or urgent target vessel revascularization within 14 days; and pharmacodynamic measures. All cases were successful, with final Thrombolysis in Myocardial Infarction grade 3 flow and no angiographic thrombotic complications. There were 2 ischemic end points in the REG1 group and 1 in the unfractionated heparin group, with 1 major bleed in the unfractionated heparin group. Median activated clotting time values rose from 151 to 236 seconds after RB006. Administration of the partial RB007 dose reversed anticoagulation to an intermediate activated clotting time value of 186 seconds. Complete reversal with RB007 returned the median activated clotting time value to 144 seconds. Both reversal strategies enabled scheduled femoral sheath removal. Conclusions: This study demonstrates the clinical translation of a novel platform of anticoagulation targeting factor IXa and its active reversal to percutaneous coronary intervention and provides the basis for further investigation.",
keywords = "angioplasty, anticoagulants, coronary disease, thrombosis",
author = "Cohen, {Mauricio G} and Purdy, {Drew A.} and Rossi, {Joseph S.} and Grinfeld, {Liliana R.} and Myles, {Shelley K.} and Aberle, {Laura H.} and Greenbaum, {Adam B.} and Edward Fry and Chan, {Mark Y.} and Tonkens, {Ross M.} and Steven Zelenkofske and Alexander, {John H.} and Harrington, {Robert A.} and Rusconi, {Christopher P.} and Becker, {Richard C.}",
year = "2010",
month = "8",
day = "10",
doi = "10.1161/CIRCULATIONAHA.109.927756",
language = "English",
volume = "122",
pages = "614--622",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - First clinical application of an actively reversible direct factor ixa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention

AU - Cohen, Mauricio G

AU - Purdy, Drew A.

AU - Rossi, Joseph S.

AU - Grinfeld, Liliana R.

AU - Myles, Shelley K.

AU - Aberle, Laura H.

AU - Greenbaum, Adam B.

AU - Fry, Edward

AU - Chan, Mark Y.

AU - Tonkens, Ross M.

AU - Zelenkofske, Steven

AU - Alexander, John H.

AU - Harrington, Robert A.

AU - Rusconi, Christopher P.

AU - Becker, Richard C.

PY - 2010/8/10

Y1 - 2010/8/10

N2 - Background: The ideal anticoagulant should prevent ischemic complications without increasing the risk of bleeding. Controlled anticoagulation is possible with the REG1 system, an RNA aptamer pair comprising the direct factor IXa inhibitor RB006 and its active control agent RB007. Methods and Results: This phase 2a study included a roll-in group (n=2) treated with REG1 plus glycoprotein IIb/IIIa inhibitors followed by 2 groups randomized 5:1 to REG1 or unfractionated heparin. In group 1 (n=12), RB006 was partially reversed with RB007 after percutaneous coronary intervention and fully reversed 4 hours later. In group 2 (n=12), RB006 was fully reversed with RB007 immediately after percutaneous coronary intervention. Femoral sheaths were removed after complete reversal. Patients were pretreated with aspirin and clopidogrel. End points included major bleeding within 48 hours; composite of death, myocardial infarction, or urgent target vessel revascularization within 14 days; and pharmacodynamic measures. All cases were successful, with final Thrombolysis in Myocardial Infarction grade 3 flow and no angiographic thrombotic complications. There were 2 ischemic end points in the REG1 group and 1 in the unfractionated heparin group, with 1 major bleed in the unfractionated heparin group. Median activated clotting time values rose from 151 to 236 seconds after RB006. Administration of the partial RB007 dose reversed anticoagulation to an intermediate activated clotting time value of 186 seconds. Complete reversal with RB007 returned the median activated clotting time value to 144 seconds. Both reversal strategies enabled scheduled femoral sheath removal. Conclusions: This study demonstrates the clinical translation of a novel platform of anticoagulation targeting factor IXa and its active reversal to percutaneous coronary intervention and provides the basis for further investigation.

AB - Background: The ideal anticoagulant should prevent ischemic complications without increasing the risk of bleeding. Controlled anticoagulation is possible with the REG1 system, an RNA aptamer pair comprising the direct factor IXa inhibitor RB006 and its active control agent RB007. Methods and Results: This phase 2a study included a roll-in group (n=2) treated with REG1 plus glycoprotein IIb/IIIa inhibitors followed by 2 groups randomized 5:1 to REG1 or unfractionated heparin. In group 1 (n=12), RB006 was partially reversed with RB007 after percutaneous coronary intervention and fully reversed 4 hours later. In group 2 (n=12), RB006 was fully reversed with RB007 immediately after percutaneous coronary intervention. Femoral sheaths were removed after complete reversal. Patients were pretreated with aspirin and clopidogrel. End points included major bleeding within 48 hours; composite of death, myocardial infarction, or urgent target vessel revascularization within 14 days; and pharmacodynamic measures. All cases were successful, with final Thrombolysis in Myocardial Infarction grade 3 flow and no angiographic thrombotic complications. There were 2 ischemic end points in the REG1 group and 1 in the unfractionated heparin group, with 1 major bleed in the unfractionated heparin group. Median activated clotting time values rose from 151 to 236 seconds after RB006. Administration of the partial RB007 dose reversed anticoagulation to an intermediate activated clotting time value of 186 seconds. Complete reversal with RB007 returned the median activated clotting time value to 144 seconds. Both reversal strategies enabled scheduled femoral sheath removal. Conclusions: This study demonstrates the clinical translation of a novel platform of anticoagulation targeting factor IXa and its active reversal to percutaneous coronary intervention and provides the basis for further investigation.

KW - angioplasty

KW - anticoagulants

KW - coronary disease

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=77955468444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955468444&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.109.927756

DO - 10.1161/CIRCULATIONAHA.109.927756

M3 - Article

C2 - 20660806

AN - SCOPUS:77955468444

VL - 122

SP - 614

EP - 622

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 6

ER -